Department of Urology, University Hospital Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany.
Eur Urol. 2009 Jul;56(1):65-71. doi: 10.1016/j.eururo.2008.12.012. Epub 2008 Dec 17.
Ureteroscopically guided laser techniques are commonly used in the treatment of upper urinary tract transitional cell carcinoma (UUTT); however, there is an ongoing debate with regard to indication and management.
To review the indication, feasibility, and treatment outcome of laser application for definitive endoscopic treatment of UUTT, focusing on technical aspects of different laser devices and their impact on tissue.
PubMed and Medline were searched for reports on laser therapy in UUTT from 1980 to 2008, with particular focus on the technical background of various laser systems.
For decades, nephroureterectomy has been considered the gold standard for treating UUTT. With the intent to preserve functioning renal parenchyma, minimally invasive approaches, initially advocated for patients requiring a nephron-sparing approach (ie, single functioning kidney, renal insufficiency or significant comorbidities), have gained widespread acceptance due to advances in ureteroscopy, percutaneous renal surgery, and laparoscopy. Ureteroscopically guided laser ablation has been used successfully, resulting in recurrence rates ranging from 31% to 65% and disease-free rates of 35% to 86%, depending on stage and grade at diagnosis.
To obtain the highest treatment success, the initial staging and grading of the tumour is crucial. Because low-grade tumours rarely if ever progress in stage or grade, the success rate of ureteroscopic therapy parallels that of endoscopic resection of identical bladder tumours. In the treatment of higher grade, advanced tumours, ureteroscopic therapy is less likely to be curative, and thus, endoscopic manoeuvres can only be palliative. Due to the relatively low prevalence of this tumour and the lack of comparable randomised, multicentre trials, the indications for an endoscopic laser treatment option has to be defined based on the patient's individual situation.
输尿管镜引导下的激光技术常用于治疗上尿路移行细胞癌(UUTT);然而,对于适应证和处理方法,目前仍存在争议。
回顾激光在 UUTT 确定性内镜治疗中的适应证、可行性和治疗结果,重点关注不同激光设备的技术特点及其对组织的影响。
检索 1980 年至 2008 年间PubMed 和 Medline 上关于 UUTT 激光治疗的报告,特别关注各种激光系统的技术背景。
几十年来,肾输尿管切除术一直被认为是治疗 UUTT 的金标准。为了保留有功能的肾实质,最初提倡对需要保留肾单位(即单个有功能的肾脏、肾功能不全或严重合并症)的患者采用微创方法,由于输尿管镜技术、经皮肾手术和腹腔镜技术的进步,这些方法得到了广泛的认可。输尿管镜引导下的激光消融已成功应用,其复发率为 31%至 65%,无疾病生存率为 35%至 86%,具体取决于诊断时的分期和分级。
为了获得最高的治疗成功率,肿瘤的初始分期和分级至关重要。由于低级别肿瘤很少进展为分期或分级,因此输尿管镜治疗的成功率与相同膀胱肿瘤的内镜切除术相似。对于高级别、晚期肿瘤,输尿管镜治疗不太可能治愈,因此内镜操作只能是姑息性的。由于这种肿瘤的相对低发病率以及缺乏可比的随机、多中心试验,内镜激光治疗选择的适应证必须根据患者的个体情况来确定。